<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127569">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667575</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2012004</org_study_id>
    <nct_id>NCT01667575</nct_id>
  </id_info>
  <brief_title>Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the efficacy of ten day triple therapy-based,
      bismuth-containing quadruple therapy for H.pylori treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success rate of currently recommended triple therapy with a proton pump inhibitor (PPI)
      plus amoxicillin and clarithromycin has fallen into the unacceptable range. The purpose of
      this study is to observe the efficacy of ten day triple therapy-based, bismuth-containing
      quadruple therapy for H.pylori treatment, while ten day triple therapy is used as control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To calculate and compare the efficacy of 10 day and 14 day triple therapies with and without bismuth,to examine whether long duration and addition of bismuth affects the eradication.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Peptic Ulcer</condition>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>10 day Quadruple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 day Triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>antisecretary drug of the quadruple therapy</description>
    <arm_group_label>10 day Quadruple Therapy</arm_group_label>
    <arm_group_label>10 day Triple therapy</arm_group_label>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
    <other_name>proton pump inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>antibiotic  of the quadruple therapy</description>
    <arm_group_label>10 day Quadruple Therapy</arm_group_label>
    <arm_group_label>10 day Triple therapy</arm_group_label>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>antibiotic of the quadruple therapy</description>
    <arm_group_label>10 day Quadruple Therapy</arm_group_label>
    <arm_group_label>10 day Triple therapy</arm_group_label>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
    <other_name>antibiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>one of a component of a quadruple therapy</description>
    <arm_group_label>10 day Quadruple Therapy</arm_group_label>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
    <other_name>Bismuth</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>long duration (14 day)</intervention_name>
    <arm_group_label>14 day quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who presented with upper gastrointestinal symptoms and endoscopically proven
             H.pylori-positive functional dyspepsia and scarred peptic ulcers

        Exclusion Criteria:

          -  patients less than 18 years old, with history of H. pylori infection treatment, with
             previous gastric surgery, pregnancy, lactation, major systemic diseases,
             administration of antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks,
             or allergy to any one of the given medication in the regimens.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 1, 2013</lastchanged_date>
  <firstreceived_date>August 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Dr. HONG LU</investigator_full_name>
    <investigator_title>Professor of GI Division</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
